Pirtobrutinib Demonstrates Favorable Efficacy in Patients With B-Cell Malignancies
Researchers sought to determine the recommended phase 2 dose, safety, and efficacy of pirtobrutinib in patients with B-cell malignancies.
Chronic Lymphocytic Leukemia
Antibody Responses After COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia
Researchers sought to determine the efficacy of the COVID-19 vaccine in patients with CLL.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
How to Manage Venetoclax Resistance in Chronic Lymphocytic Leukemia
Experts outline treatment options for patients with venetoclax resistance.
MAPK Pathway Linked to Resistance to Phosphatidylinositol 3-Kinase Inhibition in Patients With Chronic Lymphocytic Leukemia
Researchers sought to determine whether activation of MAPK pathway genes may play a role in resistance to PI3K inhibitor therapy in patients with CLL.
Therapeutic Drug Monitoring Improved Incidence of Pleural Effusion With Dasatinib for CP-CML
A dose-reduction strategy in patients with CP-CML receiving dasatinib was shown to be feasible and may reduce adverse effects in these patients.
Treatment Strategies and Challenges in Chronic Lymphocytic Leukemia
Researchers sought to clarify the current treatment strategies and challenges for patients with chronic lymphocytic leukemia.
Venetoclax Plus Obinutuzumab Prolongs PFS, Not OS, in Chronic Lymphocytic Leukemia
At 4 years, there was no significant difference in overall survival.
Acalabrutinib Seems Safe and Efficacious in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
Umbralisib Shows Promise Among Patients With CLL Intolerant to BTK, PI3K Inhibitors
Researchers sought to determine whether umbralisib would be an effective treatment option for patients with CLL who cannot tolerate BTK or PI3Kδ inhibitors.
- Loading...
Loading...
Loading... 
Loading...